Leadership

Mr. Truitt was the President and Chief Executive Officer of Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small molecule drug therapies for immune system disorders, from 2018 to January 2020. Before serving as the President and Chief Executive Officer, Mr. Truitt served in a number of various positions at Achillion, including Executive Vice President, Chief Operations Officer (2017 to 2018) and Executive Vice President, Chief Commercial Officer (2009 to 2017). Earlier, Mr. Truitt was the Vice President, Business Development and Product Strategy of Lev Pharmaceuticals, Inc. from 2006 to 2008. He also served as Vice President, Sales and Operations of Johnson & Johnson – OraPharma, Inc. from 2000 to 2006. Prior to this, Mr. Truitt spent nine years at TAP Pharmaceuticals Inc. in a variety of sales and marketing roles before doing a two-year stint as a Consultant at IMS Health. Mr. Truitt received his B.S. in Marketing from LaSalle University and his M.B.A from St. Joseph’s University. Mr. Truitt was a Captain in the United States Marine Corps.

Mr. Hutchison most recently served as the Chief Financial Officer of SwanBio Therapeutics, a private gene therapy biotech company. Before SwanBio, Mr. Hutchison served as the Chief Financial Officer of Innocoll, Inc., a private biotech company. Prior to that, Mr. Hutchison served as the Chief Financial Officer of TetraLogic Pharmaceuticals, a public biotech company, and was formerly Vice President – Finance before assuming his role as CFO. Before that, Mr. Hutchison was Teleflex, Inc.’s Vice President – Corporate Controller and Chief Accounting Officer. Before his time at Teleflex, Mr. Hutchison was Vice President – Group Controller of Cephalon, Inc., an international biopharmaceutical company. Mr. Hutchison received his B.S. degree in Accounting from the Wharton School of the University of Pennsylvania (UPenn) and also earned a B.A. degree in Psychology from UPenn.